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1. Introduction 
An efficient intercellular communication system is essential to allow the correct functioning 
of multicellular organisms. This necessitates extracellular messengers (hormones, or 
neurotransmitters) as well as receptors , that is, proteins capable of recognizing these 
extracellular messengers and transducing a signal inside the cell. Each cell expresses several 
different types of receptors: signal transduction is both temporally and spatially integrated 
in order to generate the appropriate cellular response to each physiological situation.  
Hydrophobic ligands are able to penetrate inside the cell: they recognize intracellular 
receptors that migrate to the nucleus and regulate protein transcription. Hydrophilic 
ligands, in contrast, are unable to cross the plasma membrane: these extracellular ligands 
recognize transmembrane receptors that then produce intracellular messengers to affect the 
target cell function. Several families of transmembrane receptors are known: some are 
ligand-gated ion channels, and regulate the transmembrane voltage (depolarization or 
hyperpolarisation) or the intracellular Ca++ concentration; others are ligand-activated 
enzymes: some synthetize cGMP, others phosphorylate specific target proteins upon ligand 
recognition; and yet other receptors (known as “G Protein Coupled Receptors” or “GPCRs”) 
activate intracellular trimeric G proteins in response to extracellular signals. These receptor-
activated G proteins in turn activate enzymes responsible for “second messenger” synthesis 
(adenylate cyclase  cAMP, or phospholipase C  Inositol trisphosphate (Inositol(1,4,5)P3 
or “IP3”) and diacylglycerol), regulate ion channels, or activate other (“small”) G proteins. 
2. G protein coupled receptors 
2.1 A few examples  
The human genome contains at least 800 GPCRs, grouped in five main families (Fredriksson 
et al., 2003). One of the best characterized GPCR, rhodopsin, is responsible for vision in the 
dark: it captures photons thanks to its prosthetic group (11-cis retinal), and leads to 
phosphodiesterase activation in retina rod cells. It is extremely abundant in the rod cell 
disks, comparatively easy to purify, and therefore has been very extensively studied for 
many years by biochemists. Other GPCRs allow us to taste and smell, control our appetite, 
fertility, stress, heart rate and breathing, etc. Adrenaline (the stress hormone), histamine 
(allergic reactions), glucagon (glycemia control), but also taste and odorant receptors, 
luteotropic and follicular stimulating hormone receptors (ovule and spermatozoid 
development), etc. recognize GPCRs and induce G protein activation.  
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2.2 GPCR families 
All G protein coupled receptors possess a glycosylated extracellular amino-terminal (N-
term) and an intracellular carboxyl-terminal (C-term) domain, separated by 7 
transmembrane helices (TM1 to TM7) joined by three intracellular (IC1 to IC3) and three 
extracellular (EC1 to EC3) loops (Figure 1).  
 
Fig. 1. Ribbon representation of the X-ray structure of rhodopsin. Left: schematic 
representation of a GPCR, showing the TM helices, intracellular (IC) and extracellular (EC) 
loops. Right: ribbon representation of the crystal structure of rhodopsin (1GZM). The 
prosthetic group, retinal, is covalently bound to a lysine side chain in TM7 (sticks). 
The first and second EC loops are joined by a conserved disulfide bridge. The C-term 
region begins by an intracellular ǂ-helix, H8, which lies horizontally on the plasma 
membrane: it forms an aromatic cluster with a tyrosine side chains from TM7 and 
interacts with the phospholipid head groups through lysine and arginine side chains. The 
7 helices are arranged in a bundle (Figure 1). GPCRs have been identified in animals, 
yeast, plants. They probably arise from a common ancestor (Fredriksson et al., 2003). 
Several hundred putative GPCRs have been identified in the human genome where they 
represent 1-3% of the genes (Fredriksson et al., 2003). The vast majority of GPCRs 
(including most odorant receptors) share “signature” amino acids with rhodopsin (see 
below). They have been grouped in “Family A” (Kolakowski, Jr., 1994) or “rhodopsin-like 
receptor family” (Fredriksson et al., 2003). Other GPCR families do not possess these 
highly conserved amino acids, but share other signature amino acids. For instance, all 
“family B” (secretin-receptor like) receptors possess a typical N-terminal “sushi” domain 
with three conserved disulfide bridges and have very strong sequence homologies in the 
transmembrane domain. Fifteen of these receptors with a comparatively short N-term 
domain (“sushi” domain only) are specialized in recognition of peptide hormones and 
neurotransmitters (glucagon, Growth Hormone Releasing Hormone (GHRH or GRF), 
parathyroid hormone (PTH) and others). 
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The majority of family B receptors possess several additional modules (EGF-like, 
Immunoglobulin-like, etc) before the sushi domain, suggesting that they might function as 
adhesion proteins (Mizuno and Itoh, 2011). Most of these are “orphan” receptors (that is: 
their ligand is unknown) and their ability to activate G proteins has not been proven yet. 
“Family C” receptors recognize amino acids (metabotropic receptors for glutamate and 
GABAB receptors for GABA) or calcium ions, through N-terminal “venus flytrap” domains 
(Jensen et al., 2002; Wellendorph and Brauner-Osborne, 2009). Some of the taste receptors 
also are GPCRs: sweet and “umami” tasting molecules are recognized by “family C” 
GPCRs, and the “bitter” taste, by GPCRs that present very little homology with the other 
GPCRs, and form an additional receptor family (Fredriksson et al., 2003).  
2.3 Conserved residues in “family A” receptors 
Rhodopsin and related receptors possess a few extremely conserved residues in each TM 
helix. In the Ballesteros and Weinstein nomenclature, the most conserved amino acid in each 
TM helix is numbered Xh.50 (where “h” is the helix number): for instance, R3.50 is the most 
conserved amino acid in TM3; D3.49 and Y3.51 are the two conserved amino acids 
immediately preceding and following this arginine.  
Some of these very conserved side chains are involved in structural features, like the 
prolines in helices 5, 6 and 7 that induce kinks in the TM helices. In the different family A 
receptors crystal structures (rhodopsin but also ǃ-adrenergic, adenosine, histamine H3 
receptors), the conserved asparagine of the TM7 NPxxY(x)5-6F motif is part of a hydrogen 
bond network involving TM1, TM2 (D2.50) and TM7, while the tyrosine in this motif 
constrains TM7 in contact with aromatic side chains in the C term helix 8. Other 
conserved side chains play a role in the resting and/or active receptor conformation For 
instance, the arginine of the TM3 “DRY motif” (E/DR3.50Y) at the intracellular end of the 
third transmembrane helix forms in rhodopsin a H bond network with E3.49, E6.30 and T6.34. 
The “ionic lock” R3.50-E6.30 stabilizes the resting state: it is broken up in metarhodopsin II 
(the active rhodopsin conformation). In that structure, R3.50 folds back inside the G protein 
to interact with Y5.58, thereby creating an intracellular binding pocket, able to 
accommodate the G-protein. The ionic lock is less stable in the ǃ-adrenergic receptors 
compared to rhodopsin, and this is perhaps responsible for their detectable constitutive 
activity (ability to activate G proteins in the absence of agonist) (Moukhametzianov et al., 
2011). W6.48 of the CWxP6.50 motif is in very close contact with the agonist ligands, and 
was thought to trip the switch of receptor activation by toggling between different 
rotamer conformations and thereby affecting the position of neighbouring aromatic side 
chains. Although this hypothesis is supported by computational mapping (Bhattacharya 
and Vaidehi, 2010), the toggle is not evident in the metarhodopsin II (Standfuss et al., 
2011; Choe et al., 2011) or ǃ2-adrenergic receptor crystal structures (Rasmussen et al., 
2011b; Rasmussen et al., 2011a). 
3. Trimeric G proteins 
3.1 G protein subtypes and GPCR effectors  
The G proteins that transduce the signal from GPCRs are heterotrimeric (GǂǃǄ) proteins. 
Some of the mRNAs encoding the Gǂ subunits are subject to alternative splicing so that 
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sixteen genes encode 23 known Gǂ proteins: (Birnbaumer, 2007). The Gǂ proteins are 
anchored to the plasma membrane by N-terminal myristoylation or palmitoylation. They 
can be grouped into four families based upon sequence homologies, and each GPCR has a 
preference for a single Gǂ or for a single family of Gǂ subunits. Each Gǂ subunit regulates 
one or a few effectors (Birnbaumer, 2007):  
 G proteins in the Gs (Gs/olf) G protein family stimulate adenylate cyclase,  
 G proteins in the Gi (Gi/o/t/gust/z) G protein family inhibit adenylate cyclase and/or 
regulate ion channels,  
 G proteins in the Gq/11 (Gq/11/14/15/16) G protein family activate phospholipase C, 
 G proteins in the G12/13 G protein family activate “Guanyl nucleotide Exchange 
Factors” (GEFs) that in turn activate another group of “small” (monomeric) G proteins, 
the Rho G proteins  
The carboxyl-terminal Gǂ sequence is the major determinant for receptor recognition: 
exchanging this sequence allows the construction of promiscuous chimeric G proteins that 
can be used to drive GPCR coupling to a non-physiological effector (Kostenis et al., 2005).  
There are five known human Gǃ and 12 GǄ genes (Birnbaumer, 2007). Most but not all of the 
GǃǄ and Gǂ- GǃǄ combinations are allowed. All GǄ subunits are C-terminally prenylated 
(some with geranyl-geranyl, others with farnesyl groups) and carboxymethylated: this helps 
to anchor the GǃǄ subunits to the plasma membrane. The C-terminal sequence determines 
the nature of the prenyl group (farnesyl or geranyl-geranyl) modifying the GǄ subunit; both 
the C-terminal sequence and the prenyl group play an active role in the recognition of both 
rhodopsin and phospholipids (Katadae et al., 2008). Although the literature on this subject is 
sparse, there is some evidence that other GPCRs also recognize preferentially specific GǃǄ 
subunits (Jian et al., 2001; Kisselev and Downs, 2003; Birnbaumer, 2007). The GǃǄ subunits 
recognize and regulate a growing list of effectors, including ion channels, phospholipase C 
(PLC), phosphoinositide-3’ kinase-Ǆ (PI3KǄ), various adenylate cyclase isoforms, etc. 
Different PLC isoforms respond differently to different GǃǄ isoforms; and the cardiac ATP-
inhibited inwardly rectifying K+ channel (KirATP) is either inhibited or activated by GǃǄ 
depending on the nature of the Gǃ subunit (Birnbaumer, 2007).  
3.2 G proteins as (inefficient) GTPases 
G proteins are (poor) GTPases (Birnbaumer, 2007): they hydrolyze GTP slowly to GDP + 
inorganic phosphate, then release GDP extremely slowly. The GDP release and the GTP 
hydrolysis reactions are highly regulated, accompanied by conformation changes, and used 
as molecular clocks.  
Trimeric G proteins are no exception to this rule: GTP binding is necessary to allow transient 
effectors activation (Oldham and Hamm, 2006; Birnbaumer, 2007). As summarized in Figure 
2, the GDP release from trimeric G proteins is accelerated by G Protein Coupled Receptors 
(GPCRs) that function as “Guanyl nucleotides Exchange Factors” (GEFs): they allow GDP 
release, and this is rapidly followed by GTP recognition and dissociation of the two G 
protein subunits. Both subunits can then transiently recognize their respective effectors. The 
GTP hydrolysis reaction (leading to signal interruption) is accelerated by “Regulators of G 
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protein Signaling” (RGS) proteins, that function as “GTPase Activator Proteins” (GAPs) and 
accelerate signal interruption. 
 
Fig. 2. the G protein activation cycle. In the resting state, the G protein is trimeric 
(GǂGDPGǃǄ) and occupied by GDP. GPCRs interact with resting (GDP-bound) G proteins, 
facilitate the GDP release and stabilize an empty G protein conformation. GTP induces the 
dissociation of the two G protein subunits, GǂGTP and GǃǄ: this allows both subunits to 
recognize and regulate their respective effectors (enzymes, channels or regulators of G 
protein signaling). GǂGTP hydrolyses GTP to GDP and the GǂGDP complex recognizes GǃǄ 
with a very high affinity: the resting trimeric complex reforms spontaneously. GTP 
hydrolysis can be accelerated by “Regulators of G protein Signaling” (RGS) molecules. 
3.3 G protein structures 
The G proteins regulated by GPCRs are heterotrimeric (Birnbaumer, 2007). The three 
polypeptide chains form two independent subunits: the Gǂ and GǃǄ subunits (Figure 3). 
The Gǂ protein structure can be divided into two domains held together by mutual 
interactions with the guanyl nucleotide: a N-terminal “Ras-like domain” (with strong 
structural homology with the small GTPases, Ras) and a C-terminal ǂ-helical domain 
(Figure 3). In the agonist-receptor-G protein complex, the guanyl nucleotide has dissociated, 
and the helical domain “floats away” from the Ras –like domain (Rasmussen et al., 2011b). 
The Gǃ protein “WD repeats” (blue) forms a 7 blades beta-propeller domain, and the GǄ 
protein (green) wraps around Gǃ, one of the two small ǂ-helices forming a coiled-coil with 
the Gǃ protein ǂ-helix (Figure 3). GǃǄ forms a stable complex that cannot be dissociated 
without denaturation but Gǂ can dissociate from GǃǄ upon GTP binding. 
As shown in Figure 4, the conformation of three segments (“switch regions”) of Gǂ changes 
during the GTPase catalytic cycle (Oldham and Hamm, 2006; Rasmussen et al., 2011b). This 
regulates the interaction of Gǂ with GǃǄ and with its effectors. Switch 2 together with either 
switch 1 or 3 indeed forms part of the Gǂ – protein binding interface (Figure 5). It 
participates to the recognition of GǃǄ, but also of effectors and “Regulators or G protein 
Signaling” (RGS) proteins (Figure 5): the Gǂ- GǃǄ dissociation is essential to allow effectors 
activation by GǂGTP.  
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Fig. 3. Ribbon representations of G protein structures. The Gǂ subunits are presented in 
yellow, the ǃ subunits in blue and the Ǆ subunits in green and the ǃ2-adrenergic receptor, 
in red. GDP and GTP are shown in fuchsia as space-filling structures. From left to right: 
the Gi protein (1GG2), the ǃ2 adrenergic receptor-agonist-Gscomplex (3SN6), the activated 
GǂGTP (1GIL) and Gǃ1Ǆ2 (1TBG) structures. The latter two structures have been rotated 
separately by approximately 90° compared to GǂGDPǃǄ, to show the different domains 
(center right: the ras-like and ǂ-helical domains of the Gǂ subunit; far right: a ǃ-propeller 
structure in the Gǃ subunit).  
 
Fig. 4. Effect of guanyl nucleotide binding on the Gǂ subunit conformation. Ribbon 
representation of Gǂ in different crystallized complexes : the Gǂ subunit only is shown for 
simplicity; the GǃǄ subunit when present would be in front and to the right of the Gǂ 
subunit. The N-terminal region, when structurally defined (stabilized by interactions with 
GǃǄ) is represented by a blue ribbon. Three regions change conformation during the GTPase 
catalytic cycle: “switch 1” is shown in green, “switch 2” in gold, and “switch 3” in red. GDP 
(pink), GTP (yellow) and phosphate (pink) are shown as space filling structures. Left: the 
Gǂt subunit in the GǂGDPǃǄ complex (PDB 1GOT); top center: the structure of GǂS in the 
ternary complex, HRG (PDB 3SN6), stabilized by a nanobody; right: the structure of the GTP 
analogue GTPǄS-activated Gǂt (PDB 1TND) and bottom center: the structure of Gǂi bound 
to GDP and inorganic phosphate during GTP hydrolysis (PDB 1GIT).  
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Fig. 5. Ribbon representation of Gǂ subunits in complex with GǃǄ or with their effector and 
regulator proteins, showing the side chains that belong to the protein binding site. The Gǂ 
subunit only is shown for simplicity. The amino acids that belong to the protein binding 
sites of the different Gǂ structures are shown as space filling. When structurally defined, the 
ribbon (and side chains) that belong to the N-terminal helix are shown in blue, those that 
belong to switch 1 in green, to switch 2 in orange, to switch 3 in red, and to the rest of the 
protein in light grey. Top left: the GDP-bound transducin-Gi chimera showing the 
interaction surface with GǃǄ (1GOT); top center: GTP*-bound GǂS showing the interaction 
surface with adenylate-cyclase (1CUL); top right: GTP-bound Gǂq showing the interaction 
surface with phospholipase-C (3OHM); bottom left:GTP-bound Gǂ13 showing the 
interaction surface with the Rho GEF, p115 (1SHZ); bottom center: GTP-bound transducin-
Gi chimera showing the interaction surface with the phosphodiesterase inhibitor subunit, 
PDEǄ (1FQJ) and bottom right, GTP-bound transducin-Gi chimera showing the interaction 
surface with RGS9 in a complex with PDEǄ and RGS9 (1FQK). 
GǃǄ is also capable of activating certain effectors. Its binding site for Gǂ overlaps in part the 
GǃǄ-effector and GǃǄ- regulator binding sites: the dissociation of GǂGTP from GǃǄ is 
essential to allow GǃǄ to recognize its effectors (Figure 6).  
GTP hydrolysis, rapidly followed by the release of the phosphate ion, modifies the switch 
regions conformation (Figure 4). The conformation change does not only inhibit the Gǂ-
effector interaction (Figure 5) but also favors GǃǄ recognition by GǂGDP, thereby also 
inactivating GǃǄ (Figure 6). Agonist-bound receptors interact with both G protein subunits 
(Figure 3): the formation of the “ternary complex” is an essential step for G protein 
activation, but the ternary complex Gǂ subunit is not in the right conformation to activate G 
protein effectors (Figure 3).  
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Fig. 6. Ribbon representation of GǃǄ showing the interaction surface with Gǂ or with 
effectors. Ribbon representation of GǃǄ in different crystallized complexes – the Gǃ (blue) 
and GǄ (green) subunits only are shown for simplicity. The amino acids that belong to the 
Gǂ recognition surface (PDB ref 2BCG: top), to the phosducin binding site (1GP2: bottom 
left) or to the kinase, GRK2 binding surface (bottom right : 1OMW) are shown as space 
filling structures, in yellow.  
4. G protein activation kinetics 
Rhodopsin and related receptors catalyze G protein activation (Hamm, 1998): this means 
that each receptor sequentially activates several G proteins by facilitating the release of 
GDP, thereby allowing GTP binding. Rhodopsin does not enter in one of the Enzyme 
Commission “E.C.” subclasses, as it does not catalyze the rupture or formation of covalent 
bond(s). The equations describing the reaction kinetics are nevertheless identical to those 
describing “ping pong” (double displacement) enzyme reaction (Waelbroeck et al., 1997; 
Heck and Hofmann, 2001; Ernst et al., 2007): G protein binding (substrate 1) is followed by 
GDP release (product 1), and GTP binding (substrate 2) is followed by the release of the 
activated G protein (product 2).  
The kinetics of transducin activation by rhodopsin have been analyzed in detail (Heck and 
Hofmann, 2001; Ernst et al., 2007). Rhodopsin recognizes transiently the GDP-bound trimeric 
G protein, transducin, and activates transducin at the diffusion limit (Ernst et al., 2007). The 
physiological concentrations of the two “substrates” (GDP-bound transducin and GTP) are 
close to their respective Michaelis constants, KM. In the case of double displacement 
reactions, it is unfortunately impossible to the individual rate constants of each reaction 
from the kinetic data (KM, Vmax). The [Substrate]/KM ratios at physiological concentrations 
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nevertheless strongly suggest that the concentrations of the four reaction intermediates, Rh*, 
Rh*-GGDP, Rh*-G and Rh*-GGTP (where Rh* is the light activated rhodopsin) are similar 
(Roberts and Waelbroeck, 2004): none of the reaction intermediates accumulates. These 
characteristics are reminiscent of the properties of triose phosphate isomerase and other 
“kinetically perfect enzymes” (Albery and Knowles, 1976): all the reaction intermediates 
have very similar free energies at physiological substrate concentrations and the energy 
barriers separating the different enzyme states are very low, thereby allowing the reaction to 
proceed at the diffusion limit.  
Enzymes accelerate reactions by stabilizing the “transition state”, that is, the state with the 
highest energy along the reaction coordinates. Trimeric G proteins cannot be purified in the 
absence of guanyl nucleotides: they are unstable when empty. As explained below, agonists 
stabilize the agonist-receptor-G protein ternary complex (that includes an empty G protein): 
like enzymes, active GPCRs catalyze G protein activation by decreasing the free energy of 
the transition state, that is, the empty G protein (Waelbroeck, 1999). GTP recognition by the 
G protein destabilizes the ternary complex: this induces activated G protein release - and 
allows the catalytic activation of several G proteins by a single receptor.  
5. Ligand binding studies and the ternary complex model 
Ligands that induce G protein activation are termed “agonists”, and ligands that do not 
affect the receptor activity, “antagonists”. Even at 100% receptor occupancy, some agonists 
have a larger effect than others on G protein activation: the more effective agonists are called 
“full agonists” and the less efficient compounds, “partial agonists”. More recently, it has 
been demonstrated that most GPCRs have the ability to activate (inefficiently) their cognate 
G proteins in the absence of any ligand: this is called “constitutive activity”. Compounds 
that counteract the receptors’ constitutive activity are called “inverse agonists”.  
Agonist binding to GPCRs in the absence of either GDP or GTP facilitates the formation of 
the ternary complex involving the receptor, an agonist, and an empty G protein (Figure 3) 
(Lefkowitz et al., 1976; De Lean et al., 1980; Rasmussen et al., 2011b). This is evident from the 
formation of a high molecular weight “ternary complex” (ligand-receptor-G protein, LRG) 
with a much higher affinity for agonists compared to isolated receptors. Guanyl nucleotides 
(GTP, GTP analogues or GDP) destabilize the G protein interaction with agonist-bound 
receptors by markedly decreasing the G-protein affinity for the receptor. When recognizing 
the high affinity ternary complex, guanyl nucleotides dramatically increase the agonists’ 
dissociation rate, and decrease the receptor affinity for agonists while increasing their 
affinity for inverse agonists (see for instance (Lefkowitz et al., 1976; Berrie et al., 1979)); GDP 
is typically needed in larger concentrations than GTP or GTP analogues. 
The effect of GTP on ligand binding can be used as a measure of the relative stability of 
the ternary complex compared to the binary ligand-receptor complex (Lefkowitz et al., 
1976). Full agonists have a higher affinity in the absence of GTP and inverse agonists have 
a higher affinity in its presence: the effect of GTP on ligand recognition is correlated with 
the ligands’ ability to induce or inhibit G protein activation by the receptor (Lefkowitz et 
al., 1976; De Lean et al., 1980). 
The original ternary complex model (Figure 7: top left) (Lefkowitz et al., 1976) was designed 
to describe ligand binding to GPCRs. It describes the allosteric interactions between the 
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ligand (L) and the G protein (G) recognizing different binding sites on the same receptor (R). 
Guanyl nucleotides were assumed to “prevent” G protein interaction with the receptor. The 
ternary complex model was later completed to the cubic ternary complex model (Figure 7: 
bottom right) (Weiss et al., 1996a; Weiss et al., 1996c; Weiss et al., 1996b). Two receptor 
conformations (R and R*) without and with the ability to activate G proteins respectively are 
assumed to coexist at equilibrium (RR*) in the absence and presence of ligands or G 
proteins. Agonists and G proteins favor the active (R*) receptor conformation while inverse 
agonists stabilize the inactive (R) conformation. As in the ternary complex model, the cubic 
model describes the binding (as opposed to functional) properties of GPCRs; guanyl 
nucleotides are assumed to “prevent” the receptor-G protein interaction. 
 
Fig. 7. The ternary complex model. Top left: the ternary complex model assumes that the 
receptor (R) can interact simultaneously with a ligand (L) and the G protein (G). Agonists 
facilitate and antagonists inhibit the receptor-G protein interaction; the ternary complex 
(LRG) is somehow responsible for transduction of the effect. Bottom right: the “cubic 
ternary complex model” assumes that the receptor can be found in a resting (R) or in an 
active (R*) conformation. G proteins (G) and agonist ligands stabilize R* while inverse 
agonists stabilize the R conformation. R*G and LR*G complexes are responsible for the 
biological effects of the active receptor. 
Both ternary complex models have had a tremendous impact on our vision of GPCR 
function: the agonist-receptor-G protein complex is more and more often considered as “the 
active receptor”. It should be remembered, however, that the ternary complex is certainly 
not “biologically active”: it accumulates only under conditions where the G protein is 
unable to activate its’ effectors (in the absence of GTP), and the G protein conformation in 
the ǃ-adrenergic receptor-G protein complex (Figure 3) is not compatible with GS-adenylate 
cyclase interaction (Figure 5)! The ternary complex model was designed to describe ligand 
binding to the receptors, as opposed to effectors activation. 
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6. “Resting” and “active” receptor structures 
When rhodopsin is illuminated, its conformation passes through a number of intermediates 
(bathorhodopsin (t1/2 50ns), lumirhodopsin (t1/2 50µs), followed by metarhodopsin I and II) 
before releasing the all-trans retinal. Metarhodopsin II is biologically active: it catalyses G 
protein (transducin) activation.  
The three dimensional structure of rhodopsin and several “family A” GPCRs has been 
elucidated by X-ray crystallography in the absence and presence of antagonists, agonists, G 
protein surrogates, or of the trimeric-Gs protein (Choe et al., 2011; Lebon et al., 2011; 
Rasmussen et al., 2011a; Rasmussen et al., 2011b; Rosenbaum et al., 2011; Standfuss et al., 
2011; Warne et al., 2011; Xu et al., 2011). A conserved ionic bond between rhodopsin arginine 
135 (R3.50) (in the conserved E/DRY motif at the intracellular end of TM3) and glutamate 247 
(E6.30) , at the end of the third intracellular loop-TM6 junction tethers rhodopsin TM3 to 
TM6. In antagonist-bound ǃ2-adrenergic receptors this hydrogen bond between the 
conserved arginine and glutamate is not visible in the crystal and ǃ2-adrenergic receptors 
are known to activate slightly their cognate GS G protein even in the absence of agonist; the 
ionic bridge is less stable than in rhodopsin (Moukhametzianov et al., 2011). 
 
Fig. 8. Resting and activated GPCR conformations. Ribbon representation of the IC and 
TM regions of rhodopsin (1GZM), metarhodopsin II (3PXO), metarhodopsin II – Gt C-
term complex (3PQR), antagonist-bound ǃ2-adrenergic receptor (2RH1), agonist-bound ǃ2-
adrenergic receptor (3PDS) and agonist-GS (Cterm) bound ǃ2-adrenergic receptor (3SN6), 
seen from the cytosol. The conserved TM3 arginine (R3.50), TM5 tyrosine (Y5.58) and TM6 
glutamate (E6.30) side chains are shown in red, yellow and blue respectively. The C-
terminal transducin peptide (top right) and the C-terminal region of GǂS (bottom right) 
are shown as green ribbons. 
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In contrast with (dark adapted) rhodopsin, a large intracellular binding pocket is present 
between the TM helices of metarhodopsin II (Choe et al., 2011): the distance between the 
conserved arginine (R3.50) at the intracellular end of TM3 (E/DRY motif) and the conserved 
glutamate at the junction between the third intracellular loop and TM6 (E6.30) increases from 
less than 3.3Å in rhodopsin (PDB 1GZM), bathorhodopsin (PDB 2G87) and lumirhodopsin 
(PDB 2HPY) to >15 Å in opsin (PDB 3CAP, 3DBQ) and metarhodopsin II (PDB 3PQR, 3PXO) 
(Figure 8). Arginine R3.50 forms in opsin and metarhodopsin II a strong ion-dipole interaction 
with the conserved tyrosine, Y5.58 in TM5. The G-protein binding pocket is created by the 
rotation of TM 5 and 6. It is large enough to accommodate the C-terminal helix of the 
transducin Gǂ subunit or of GǂS, at almost 40° from the membrane surface (Park et al., 2008; 
Scheerer et al., 2008; Choe et al., 2011) (Figure 8): this movement forces the opening of the GDP 
binding pocket and release GDP from the G protein (Rasmussen et al., 2011b).  
The sixth transmembrane helix (TM6) of the crystallized ǃ1-, ǃ2-adrenergic and adenosine 
A2A receptors remains very close to TM3 even in the presence of agonists (Rasmussen et al., 
2011a; Rosenbaum et al., 2011; Warne et al., 2011); and the conserved E/DRY motif arginine 
folds towards the cytoplasm, in the direction of the conserved TM6 glutamate: the G protein 
binding pocket is unavailable (Figure 8). An open, “metarhodopsin II-like” structure is 
achieved by ǃ2-adrenergic receptors only in the presence of a G protein surrogate or of GS 
(Rasmussen et al., 2011a; Rosenbaum et al., 2011; Rasmussen et al., 2011b): TM5 and TM6 
rotate away from TM3, and the arginine side chain R3.50 toggles away from the IC loop E6.30 
towards the conserved tyrosine, Y5.38.  
6.1 Is the “active receptor” mobile or rigid? 
It is well known that crystallization rigidifies proteins and can lead to selection of an 
unusual conformation stabilized by “within the crystal” (non physiological) protein-protein 
interactions. For instance, opsin and metarhodopsin II conserve the same “opened” 
conformation in the crystal in the absence and presence of a transducin surrogate (Figure 8) 
(Altenbach et al., 2008). Nevertheless, opsin – in contrast to metarhopsin II – has a very low 
ability to activate transducin: it is thus clear that crystallization of opsin “selected” a protein 
conformation with a low probability in intact membranes, stabilized through its contacts 
with other opsin molecules in the crystal.  
X-ray diffraction studies have a tremendous impact on our perception of protein structure: 
they enhance the impression that proteins are rigid molecules with a well defined, stable 
conformation. In addition, the activity of most allosteric enzymes can explained in terms of 
two conformations with very different enzyme activities, stabilized by allosteric enhancers 
and inhibitors, respectively (Monod et al., 1965). This is not an absolute rule, however: some 
enzymes change markedly in conformation upon substrate binding and dissociation – a 
phenomenon known as “induced fit” (Ma and Nussinov, 2010) and this can play an 
important role in enzyme regulation (Heredia et al., 2006; Molnes et al., 2011).  
As suggested above, the ternary complex model had a tremendous impact on the way we 
understand GPCR activation, to the extent that the agonist-receptor-(empty) G protein 
complex is now described as “the” (one and only?) active receptor conformation – despite 
the fact that the Gǂ subunit conformation in the ternary complex (Figure 3) is not 
compatible with effectors activation. This interpretation was further supported by the initial 
computational mapping of conformational energy landscape of the ǃ2-adrenergic receptor: 
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preliminary results (Bhattacharya and Vaidehi, 2010) indeed suggested that full agonists-
bound receptors switch spontaneously to a more stable, active conformation very similar to 
metarhodopsin II. Detailed computational mapping in the presence of water and lipid 
molecules of rhodopsin (Provasi and Filizola, 2010) and of the agonist-bound ǃ2-adrenergic 
receptor (Niesen et al., 2011) however indicate that both proteins are flexible and able to 
sample a large number of conformations. In the case of the ǃ2-adrenergic receptor, 
reversible “shearing” movements of TM5-6 relative to TM 1-4 and 7 and “breathing” 
movements (opening and closing of the ligand binding pocket) have been predicted. 
In the case of traditional receptors (including the ǃ2-adrenergic receptor), GTP has a 
tremendous effect on agonists’ recognition: agonists have a significantly lower affinity and 
much greater dissociation rate in the presence of GTP. This suggests that the predominant 
receptor conformation under “functional” conditions (in the presence of GTP) is different 
from the ternary complex conformation (that accumulates in the absence of GTP). I should 
like to suggest that most GPCRs are able to recruit G proteins while in the “closed” (low 
agonist affinity) conformation (Hu et al., 2010), open a G protein binding pocket and force 
GDP release to achieve the “high affinity” (ternary complex) conformation, then return to 
the “closed” conformation upon GTP recognition and activated G protein release. Agonists 
do not only facilitate the transition between the “closed” and “opened” conformations 
described by X-ray diffraction, but also decrease the free energy difference between the 
ternary complex and uncoupled receptors, thereby stabilizing the empty G protein 
conformation and facilitating GDP release, GTP binding. G protein dissociation from the 
receptor is then necessary to complete G protein activation.  
6.2 Partial GPCR activation: Agonist efficacy 
Some compounds seem less efficient than others to activate G protein coupled receptors: the 
rate of G protein activation by agonist-bound receptors varies depending on the ligand. Two 
explanations are usually put forward to account for this very common observation: partial 
agonists might stabilize the same “active” receptor conformation as full agonists but to a 
lesser extent; alternatively, they might stabilize an alternative receptor conformation, not 
quite as appropriate as the conformation induced by full agonists for G protein activation. 
These two explanations are non-exclusive and both explanations might in fact be correct at 
least where ǃ2-adrenergic agonists are concerned (Bhattacharya and Vaidehi, 2010). Indeed, 
while dopamine was predicted to stabilize (less efficiently) the same “opened” receptor 
conformation as norepinephrine, salbutamol was predicted to stabilize a slightly different, 
less opened, receptor conformation. Yet a third explanation has been suggested for 
muscarinic receptors: agonists dissociate from muscarinic receptors with a rate constant 
comparable to the G protein exchange reaction rate. The efficacy of agonists activating M3 
muscarinic receptors was correlated with their dissociation rate constant, suggesting that the 
G protein activation reaction can be aborted prematurely if the agonist dissociates too early 
in the reaction cycle (Sykes et al., 2009). 
7. Do GPCRs function as monomers or dimers? 
GABAB receptors (a “family C” GPCR) function as obligate dimers (Jones et al., 1998; White 
et al., 2002). One of the two subunits is trapped intracellularly by an endoplasmic reticulum 
retention signal; the second forms non-functional homodimers. Upon coexpression, 
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formation of a heterodimer is driven by dimerization of the N-terminal region, and by 
formation of a coiled coil by the C-terminal regions ǂ-helices. This masks the E.R. retention 
signal of the first subunit, and allows the expression of the functional heterodimer at the 
plasma membrane, (Jones et al., 1998; White et al., 2002). Likewise, all other family C 
receptors form heterodimers. 
Rhodopsin, the best known “family A” GPCR, forms quasi crystalline arrays in rod cells disk 
membranes: this led to the suggestion that not only family C receptors but all GPCRs might 
function as homo- or heterodimers. Non-radiative energy transfer between two fluorophores 
(“FRET”) or from a luminescent protein to a fluorophore (“BRET”) can be easily demonstrated 
if the “donor” and “acceptor” molecules are close enough (typically less than 50 Å from each 
other). Chimeric constructs including “donor” and “acceptor” proteins (luciferase, fluorescent 
proteins from jellyfish, etc.) and the protein of interest can be built by molecular biology 
techniques; alternatively, the donor and acceptor fluorophores can be tagged chemically to the 
protein of interest, or to an antibody raised against this protein. BRET and FRET have been 
used to demonstrate not only protein-protein interaction, but also conformational changes of a 
single protein (by tagging for instance the N- and C-terminal of the protein of interest). In 
analogy with “family C” receptors, the vast majority of family A and several family B 
receptors have been shown by BRET or FRET experiments to either dimerize or oligomerize. 
This idea raised a lot of interest, because the potential consequences of dimerization are so 
multiple and important (Milligan, 2009; Milligan, 2010; Birdsall, 2010):  
 Dimerization is essential for “family C” receptor expression at the plasma membrane 
(Temussi, 2009)) and might play a role in several other systems;  
 Dimerization affects the “pharmacology” of some receptors. For instance: the sweet 
taste is sensed by a T1R2-T1R3 heterodimer, while “umami” is detected by a T1R1-T1R3 
heterodimer (Temussi, 2009) (NB. The bitter taste is sensed by a non-family C GPCR, 
the T2R receptor; and salt and acid are recognized by “ligand gated channels” receptors 
(Temussi, 2009)). Likewise, dimerization of some GPCRs (i.e. dopamine, opiate or taste 
receptors) has been shown to alter their pharmacological properties - suggesting that 
their interaction is stable enough to affect the receptor conformation (Milligan, 2010; 
Milligan, 2009). Negative cooperativity has been observed between agonists binding to 
TSH and chemokine receptor dimers (Springael et al., 2005; Urizar et al., 2005)): binding 
of one agonist ligand to the dimer decreased the affinity of the second agonist by 
increasing its dissociation rate.  
 Dimerization may have important functional consequences: a single agonist is sufficient 
for activation of GS by the TSH receptor, but (low affinity) double occupancy of the 
dimer is necessary to support the activation of Gq/11 proteins and of phospholipase C 
(see below). 
 Most if not all GPCRs do not only interact with G proteins, but also with other 
associated proteins, often in an agonist-modulated manner (Magalhaes et al., 2011). Two 
receptors rather than one might be necessary to form optimal interactions with the 
receptor-associated proteins; alternatively, interaction of one subunit in the dimer with 
an associated protein might hinder or prevent the recognition of the second receptor 
subunit by steric hindrance, leading to “half of the sites reactivity”. 
 Several of the receptor-associated proteins act as scaffolds, recruiting in their turn other 
proteins in the vicinity of the receptor and of each other (Magalhaes et al., 2011). 
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Dimerization of the receptors might be necessary to bring together some of the different 
accessory proteins recruited by each monomer. 
It is unfortunately necessary to reassess the presence and consequences of dimerization for 
each receptor of interest: no generalization can be made in this respect. Indeed:  
 Monomeric rhodopsin and ǃ-adrenergic receptors, isolated and reconstituted in high 
density lipoprotein particles, function normally (Whorton et al., 2007; Whorton et al., 
2008); and the receptor associated proteins arrestins, like GRKs, are able to recognize 
one receptor per protein (Hanson et al., 2007; Bayburt et al., 2011).  
 Muscarinic M1 receptors dimerize only transiently: monomeric and dimeric forms are 
present at comparable concentrations in the plasma membrane at equilibrium and 
dimers dissociate rapidly ((Hern et al., 2010); see also (Johnston et al., 2011)). Cross-talk 
between two or more receptors is likely to necessitate strong interactions between the 
different monomers. 
 Muscarinic M3 receptors (McMillin et al., 2011) (and perhaps other receptors: (Johnston 
et al., 2011)) are able to use several dimerization interfaces: this might explain why so 
many different dimerization interfaces have been observed when studying different 
receptors. This does not support the hypothesis that proteins like arrestin, G proteins or 
receptor kinases need a dimer for receptor recognition: the relative position of the two 
receptor monomers would be very important in that case. 
8. Receptor promiscuity and biased signaling 
GPCR “promiscuity” is defined as the ability of a given receptor to activate several different 
effectors (for review: (Hermans, 2003). While most receptors can probably induce parallel 
signaling by the GǂGTP and GǃǄ subunits (see above), some are capable of activating 
different G proteins; and some use both G protein dependent and G protein independent 
signaling pathways. 
“Biased signaling” refers to the observation that when receptors two or more signaling 
pathways, a few agonists preferentially use only one of the signaling pathways available to 
the other agonists – an observation that suggests that the activated receptor takes different 
conformations, depending on the agonist occupying its binding site. 
8.1 Activation of several G protein subtypes by the same receptors 
Each cell expresses several G proteins, belonging or not to the same family: all these G 
proteins will compete for recognition of each activated GPCR. Most Gi-coupled receptors 
activate several Gi isoforms with variable efficiency; some Gi and GS coupled receptors 
activate in addition Gq/11 G proteins - less efficiently, or only at much higher agonist 
concentrations... Does this reflect a lower (but measurable) affinity of the non-cognate G 
protein, or less efficient activation? 
GPCRs catalyze G protein activation: they should be considered like honorary enzymes. If 
several substrates compete for transformation by the same enzyme, the proportion of 
substrates transformed by the enzyme per minute, at steady state, is proportional to their 
relative substrate concentration over specificity constant ratios, [S]/KS :  
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 ). 
The equation is extremely similar to the equation describing the competition of several 
ligands for the same receptor: the proportion of receptor occupied by each ligand ([RA] and 
[RB]) is proportional to their relative ligand concentration over dissociation constant ratios: 
 
 
 
 
A
D
B
D
RA A K
RB B K
  (2) 
The meaning of “KD” and “KS” is however very different: the dissociation constant, KD = 
1/Kaffinity, is a concentration. It measures the ligand concentration necessary to occupy, at 
equilibrium and in the absence of competitors, 50% of the receptors. The specificity constant 
KS, in contrast is a bimolecular reaction rate constant and measured in M-1sec-1. It measures 
the rate of formation of the “productive complex”, ES† in the absence of alternative 
substrates of inhibitors. 
Multiple G protein signaling has more often been observed in transfected systems, where it 
depends on the receptor expression level (for review: (Hermans, 2003)). Transiently 
expressed ǂ2 adrenergic receptors inhibit adenylate cyclase at low agonist concentrations 
but activate the enzyme at high agonist concentrations (Fraser et al., 1989). Adenylate 
cyclase inhibition but not activation is prevented by Gi protein inactivation by pertussis 
toxin (Fraser et al., 1989): these results indicate that ǂ2 adrenergic receptors are capable of 
activating both Gi and GS. The equations above predict that the relative activation rate of 
“Gi” and “GS” is proportional to their relative concentrations. Activation of GS by ǂ2 
adrenergic receptors is observed only at very high agonist concentrations: this suggests that, 
at very high agonist concentrations, Gi becomes unable to compete for receptor activation: 
in contrast with Gi-GDP, the activated Gi-GTP complex is probably unable to recognize 
agonist-bound ǂ2 adrenergic receptors (Waelbroeck, 2001). 
A few GPCRs are capable of activating several G proteins in physiological settings: the G 
protein specificity is not always “absolute”. Although this is unusual in Family A, some G 
protein coupled receptors can be expressed as related isoforms due to alternative splicing of 
RNA expressed from a single gene or to RNA editing: this may lead to receptor isoforms 
with different abilities to activate G proteins (Hermans, 2003; Bresson-Bepoldin et al., 1998). 
Alternatively, post-translational modifications such as phosphorylation of the receptor may 
alter its G protein specificity: ǃ2-adrenergic receptors activate GS proteins, leading to 
adenylate cyclase and protein kinase A stimulation, then – after phosphorylation by protein 
kinase A – activate Gi proteins (Zamah et al., 2002). The TSH receptor is able to activate G 
proteins from all four families (Allgeier et al., 1997; Laugwitz et al., 1996). Its binding 
properties are compatible with the hypothesis that it forms a stable dimer, and that 
occupancy of the dimer by one TSH molecule decreases the affinity of the second binding 
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site (“negative cooperativity” (Urizar et al., 2005)). While signaling through GS is induced at 
very low TSH concentrations, low affinity occupancy of two binding sites per dimer appears 
to be necessary to drive receptor activation of Gi (Allen et al., 2011). 
8.2 GPCR phosphorylation and desensitization 
Activated rhodopsin (metarhodopsin II) activates the rhodopsin kinase (GRK1), which in 
turn phosphorylates preferentially the activated rhodopsin (Premont and Gainetdinov, 
2007). Both activation to metarhodopsin II and phosphorylation synergistically increase the 
rhodopsin affinity for an adaptor protein, arrestin. This protein competitively inhibits 
transducin recognition by steric hindrance – resulting in rhodopsin desensitization: light 
activated rhodopsin becomes unable to activate transducin and signaling is “arrested”. 
Likewise, ligand-activated GPCRs recognize and activate “GRKs” (G protein coupled 
Receptor Kinases), that in turn preferentially phosphorylate activated GPCRs (Premont and 
Gainetdinov, 2007; Huang and Tesmer, 2011). Most GPCRs are, in addition, targets for 
“second messenger activated kinases”: they possess consensus sequences for protein kinase 
A that is activated in response to the increased cAMP, or for protein kinase C, activated by 
the phospholipase C signaling pathway (cytosolic Ca2+ and diacylglycerol). Receptor 
phosphorylation by these kinases will lead to “heterodesensitization”, since a given agonist 
can induce the desensitization of receptors it does not activate. 
Mammalian cells express seven GRKs: two of them (GRK1 and 7) are found only in rod and 
cone cells in the retina; GRK4 is found mainly in the testes and to a lesser extent in some 
brain regions and in the kidney, and the last four (GRK2, 3, 5 and 6) are ubiquitous (Yang 
and Xia, 2006). They can be subdivided in three subgroups: GRK1 and 7; GRK2 and 3, and 
GRK 4, 5 and 6. The C-terminal region of GRK2 and 3 is longer than in other GRKs and 
possesses a “Pleckstrin Homology” (PH) domain: these two GRKs are cytosolic and 
recruited by GǃǄ in response to G protein activation (Yang and Xia, 2006). In contrast, GRK 
1 and 7 are C-terminal farnesylated, GRK4 and 6 are palmitoylated on C-terminal cysteines 
and GRK4-6 have a highly conserved binding site for phosphatidyl inositol 4-phosphate: the 
PH domain and post-translational modifications facilitate the permanent localization of 
these GRKs at the plasma membrane (Yang and Xia, 2006). The N-terminal region of all 
GRKs is similar and important for receptor recognition – GRKs are highly specific in their 
receptor preference (Yang and Xia, 2006).  
Three dimensional structures for at least one representative of the three GRK families have 
been determined by X-ray diffraction (Figure 9). In most structures, the N-terminal region 
(that is essential for receptor recognition) is undefined, and the active cleft is too “open” for 
substrate recognition, suggesting that the kinases usually crystallize in the resting 
conformation. Very recently, GRK6 was crystallized in a form very likely resembling its’ 
active conformation, with a relatively “closed” active cleft (Figure 10): this structure 
probably resembles the active GRK (Boguth et al., 2010). It is characterized by a well defined 
extended N-terminal ǂ-helix, that could easily be fitted – superimposed on the G protein C-
terminal ǂ-helix (Boguth et al., 2010) - in the intracellular pocket formed in the 
metarhodopsin II structure (Figure 10). This would bring the active cleft in close proximity 
to the receptors IC3 and Cter – the two regions that are phosphorylated by GRKs.  
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Fig. 9. Representative X-ray structures of GRKs from the three families. Ribbon structure of 
GRK1 (left: 3C4W), of the GRK2-GǃǄ complex (center: 3KRW), and of the presumed “active 
conformation” of GRK6 (right: 3DQB) superimposed on the transducin C-term peptide in 
close apposition with the metarhodopsin II structure (3NYN), to form a hypothetical active 
GRK-receptor complex (according to (Boguth et al., 2010)). The GRKs are shown by a yellow 
ribbon, co-crystallized ATP or ATP analogues in pink to identify the active site; Gǃ and GǄ 
is shown in blue and green, respectively, and metarhodopsin II, in light grey. 
Most GRKs are probably able to regulate GPCR signal transduction by phosphorylation-
independent mechanisms. All GRKs have a “Regulator of G protein Signaling (RGS) 
homology” (RH) domain, and GRK2 and 3 have been shown to specifically interact through 
this domain with Gǂq family members, thereby blocking their interaction with their effector, 
phospholipase C (see Figure 5). At least some GRKs are able to compete with G protein 
recognition by the activated receptor and/or compete with effector proteins for GǃǄ 
recognition (Yang and Xia, 2006). By phosphorylating the receptor, they also increase 
markedly the receptor affinity for “arrestin” molecules that compete with G proteins for 
receptor recognition, facilitate receptor internalization in endosomes, and may serve as 
“scaffold”, allowing “G protein independent signaling” (see below) (Premont and 
Gainetdinov, 2007; Huang and Tesmer, 2011). 
Since GRKs and G proteins compete for the same (active) receptor conformation, the 
sequence of receptor recognition is important: GPCRs should recognize first the G 
proteins, then GRKs. “Sequential” recognition of two ligands is easily explained under the 
assumption that they have different dissociation rate constants (Motulsky and Mahan, 
1984): the ligand with the faster dissociation rate constant will occupy the receptor 
rapidly, then progressively give place to the ligand with the slower dissociation rate 
constant (see Figure 10). 
The most important factor under non equilibrium conditions is the relative dissociation (not 
association) rate constant of the two ligands. This might seem counterintuitive, but can 
easily be explained. Let us first examine the case of two ligands with different affinities due 
to different association rate constants. The lower affinity ligand will be needed in larger 
concentrations to significantly occupy the receptors at equilibrium: its lower association rate 
constant is then automatically compensated by the larger ligand concentration used. (The 
association rate is equal to kon[L], where kon is the association rate constant and [L], the 
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ligand concentration). In contrast, if the two ligands have different affinities because of 
different dissociation rate constant: the larger dissociation rate constant of the low affinity 
ligand cannot be compensated by the larger ligand concentrations used to occupy the 
receptor at equilibrium: the dissociation rate, koff[LR] does not depend on the free ligand 
concentration. In order for the G protein, GRKs (and arrestin) to recognize sequentially the 
receptors, it is therefore necessary and sufficient that they have a different dissociation rate 
constants from the receptor. This is not a problem, as a very rapid G protein dissociation 
from the receptor is also necessary to allow receptor recycling and efficient catalytic 
activation of the G proteins… 
 
Fig. 10. Competitive binding of two ligands to the same receptor as a function of time. 
Ligand A (full line) has a kon=108M-1min-1, koff = 1 min-1 and is present at a concentration of 
100 nM (10 KD); it will occupy 24% of the receptors at equilibrium in the presence of ligand 
B. Ligand B (hatched line), has the same kon = 108min-1M-1, a lower dissociation rate (koff = 
.0.1 min-1) and is present at a concentration of 30 nM (30 KD): it will occupy 73% of the 
receptors at equilibrium, in the presence of ligand A.  
8.3 Arrestin recognition by GPCRs 
All mammalian cells express at least one of the four “arrestins”: rod and cone cells from the 
visual system express arrestins 1 and 4, respectively; arrestins 2 and 3 (also known as ǃ-
arrestin 1 and 2) are ubiquitously expressed. These proteins recognize and are activated by 
multi-phosphorylated, activated GPCRs: arrestin (arrestin 1) is specific for rhodopsin, 
arrestin 4, for the iodopsins, and arrestins 2 and 3 recognize most if not all GPCRs. 
Phosphorylation and receptor activation synergistically enhance rhodopsin-arrestin 
interactions: light activated rhodopsin and resting but phosphorylated rhodopsin have a 10-
100 fold lower affinity for arrestin, and rhodopsin does not detectably interact with arrestin 
1. ǃ-arrestin binding to “traditional” GPCRs is affected more by phosphorylation than by 
agonist binding (Gurevich et al., 1995). 
All known arrestin 3D structures are rather similar to visual arrestin (Figure 11). They can be 
subdivided into two concave ǃ-sheet domains held together by a hinge region, an ionic 
bridge network between two arginine and three aspartate side chains (center of the structure 
on Figure 11), and by interactions between the C-term tail, the first N-term ǃ strand and the 
ǂ helix (left of Figure 11).  
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Fig. 11. The visual arrestin 1 crystal structure 1CF1. The N-terminal lobe is shown on the left, 
and the C-terminal lobe on the right. They are joined by a single random coil stretch 
(yellow) but held together through ionic interactions between buried arginine (blue) and 
aspartate (red) side chains, and by close contacts of the first N-terminal ǃ-sheet stretch and 
ǂ-helix with a C-terminal ǃ-sheet stretch (orange). The two lysine side chains that are 
important for preferential phosphorylated>non-phosphorylated (light activated) rhodopsin 
recognition are shown in orange (left).  
Each of the two arrestin domains is large enough to interact with a rhodopsin monomer 
(Figure 12). Even though visual arrestin forms a one to one complex with rhodopsin both in 
vitro (Bayburt et al., 2011) and in vivo (Hanson et al., 2007), several side chains covering both 
domains are implicated in rhodopsin recognition or rhodopsin – GPCR discrimination 
(Bayburt et al., 2011; Vishnivetskiy et al., 2011; Skegro et al., 2007) (Figure 12). This indicates 
that arrestin undergoes a significant conformation change when it recognizes the 
phosphorylated receptors. This is confirmed by the observation that the arrestin sensitivity 
to proteolytic degradation increases upon GPCR recognition, and that the intramolecular 
BRET between the N- and C-terminal region of a luciferase–arrestin–Yellow Fluorescent 
Protein (YFP) construct is markedly affected by arrestin recognition of agonist-bound 
receptors (Shukla et al., 2008). 
At least two rhodopsin Ser/Thr must be phosphorylated to allow arrestin interaction with 
metarhodopsin; three phosphates support stronger arrestin binding, and heavier 
phosphorylation promotes arrestin binding , in addition, to neighbouring dark (inactive) 
rhodopsin and to phospho-opsin, two unpreferred rhodopsin forms (Vishnivetskiy et al., 
2007). Likewise, ǃ-arrestin recognition increases mainly in response to multi-
phosphorylation of the GPCRs C-terminal or IC3 sequence rather than in response to agonist 
binding (Gurevich et al., 1995; Oakley et al., 2000). “Phosphoserine/phosphothreonine rich” 
patches are necessary for stable, high affinity arrestin recognition (Oakley et al., 2001). 
GPCRs that present patches of phosphorylated Ser/Thr residues (angiotensin II type 1A, 
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neurotensin 1, vasopressin V2, thyrotropin-releasing hormone and substance P receptors) 
have a high affinity and do not discriminate the arrestin 1, 2 and 3 isoforms; they are rapidly 
internalized and recycle inefficiently or not at all. In contrast, ǃ2-adrenergic, µ opioid, 
endothelin type A, dopamine D1A, and ǂ1b adrenergic receptors (with separate 
phosphorylated Ser/Thr residues) have a low affinity for ǃ-arrestin 2 (arrestin 3), an even 
lower affinity for ǃ-arrestin 1 (arrestin 2) and do not detectably recruit arrestin 1. Upon 
internalization, these receptors are rapidly dephosphorylated and recycled to the plasma 
membrane (Oakley et al., 2000).  
  
Fig. 12. Arrestin 3 (ǃ-arrestin 2), close to opsin structure. Grey ribbon: arrestin 3 ribbon 
structure structure (1JSY), showing some of the side chains that are immobilized upon dark 
phosphorhodopsin recognition (light green), involved in the discrimination of light 
activated phosphorhodopsin from carbachol-activated phosphorylated M2 muscarinic 
receptor (yellow) or necessary for recognition of the phosphoserine/threonines (tan) 
(Vishnivetskiy et al., 2011). Green ribbon: opsin structure 3CAP is shown for size 
comparison. 
Arrestins change conformation upon receptor recognition (Shukla et al., 2008) and behave as 
receptor-dependent “scaffold proteins” bringing together a number of other proteins (for 
review: (Premont and Gainetdinov, 2007; DeFea, 2011)). Some of their binding sites are 
shown in Figure 13. 
Several ǃ-arrestin scaffolds have been identified: this protein can recruit either MAP kinase 
partners, PI3Kinase or Akt, phosphodiesterase of actin assembly proteins scaffolds when 
bound to activated, phosphorylated receptors (DeFea, 2011). The different binding sites are 
very close (Figure 13): only some well-defined complexes can be formed or dissociated in 
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response to agonist-receptor recognition by arrestin. The factors determining which complex 
is formed in response to a given receptor are still elusive.  
 
Fig. 13. Scaffolding sites on arrestin. Top: 3 arrestin 3 structure 3P2D The Proline-rich 
regions that allow SH3 domains recognition are shown in fuchsia, the PIP2 binding site, in 
blue and side chains essential for ǃ-adaptin binding, in green. The clathrin recognition site 
LφxφE is in the hatched (unstructured) region. R307, that is essential for cRaf1 recognition, 
is shown in light blue. Bottom : arrestin 2 structure (1JSY) showing the partially overlapping 
Ask1 and MEK binding regions (kaki), the MKK4 (dark green), PDED5 (light green), ERK2 
(fuchsia) binding sites, and the partially overlapping Akt and clathrin binding sites (light 
blue) (according to (DeFea, 2011)). 
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